PE Anti-IGFBP7 antibody [EPR11912(B)],Abcam,AB211615

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human, Human

Application

IHC-P, Flow Cyt (Intra), ICC/IF

Conjugate

PE

Platform ID

BAB801027260

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NamePE Anti-IGFBP7 antibody [EPR11912(B)]
Cat. No.AB211615
HostRabbit
IsotypeIgG
ReactivityHuman, Human
ConjugationPE
ApplicationIHC-P, Flow Cyt (Intra), ICC/IF
ClonalityMonoclonal
Clone NumberEPR11912(B)
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Binds IGF1 and IGF2 with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion. Acts as a ligand for CD93 to play a role in angiogenesis (PubMed : 38218180). See full target information IGFBP7

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.